The TCR repertoire provides a novel platform for investigating the modulation of the TME post-TACE and the underlying mechanisms governing tumor development and recurrence. Clarifying the distinctive ...

In this study, the researchers analyzed more than 275 million T-cell receptor sequences from over 2,200 individuals and used artificial intelligence ...

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks.

Jefferson Health oncologist Jennifer Johnson had exhausted all the standard treatment options for her 49-year-old patient with esophageal cancer, who was likely to die within months. Surgery, ...

The gray portion of this schematic represents a nanodisc, where for the first time researchers were able to replicate the native membrane environment (red dots) of a T-cell receptor (cyan). One of the ...

COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology, a leading Texas-based viral vector Contract Development and Manufacturing Organization (CDMO), has announced a strategic partnership with ...

Secondary primary malignancies (SPMs) with CAR-T cell therapy in RR-DLBCL from real-world data. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...

The TIME trial: Phase II randomized controlled trial of time-of-day–specified immunotherapy for advanced melanoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

Advances in cell and gene therapy have led to U.S. Food and Drug Administration approved adoptive cell therapies to treat hematological malignancies and solid tumors. There is great enthusiasm in the ...

Captain T Cell GmbH has successfully closed an equity financing round to support its T-cell receptor (TCR) T-cell therapies for solid tumors. The company’s autologous lead program, CTC-127, is a ...